DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors), MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants)

Therapeutic Areas

Other DiseasesNeoplasmsImmune System Diseases+ [10]

Active Indication

InflammationLocalized Prostate CarcinomaAdenocarcinoma of prostate+ [35]

Inactive Indication

Aberrant Crypt FociAdvanced cancerColitis, Ulcerative+ [5]

Originator Organization

The University of Texas MD Anderson Cancer Center

Active Organization

The University of Texas MD Anderson Cancer Center

Nova Southeastern University, Inc.

University of Oklahoma

+ [40]

Inactive Organization

University of Illinois

Sanjay Gandhi Post Graduate Institute of Medical Sciences

Seattle Children's Hospital

+ [4]

License Organization-

Drug Highest PhaseApproved

First Approval Date-

RegulationOrphan Drug (United States)

Structure/Sequence

Molecular FormulaC21H20O6

InChIKeyVFLDPWHFBUODDF-FCXRPNKRSA-N

CAS Registry458-37-7

644

Clinical Trials associated with Curcumin

CTRI/2024/11/076875

/ Not yet recruitingPhase 4

A Single Center, Randomized, Double blind, Placebo Controlled Pilot Study to Evaluate the Efficacy, Safety and Tolerability of Turmeric Lemonade Energy Drink (Bioactive Curcumin Plus Green Tea Plus Ginger Plus Lemon Plus Lime) manufactured by Golden Tiger Life Corp in the Treatment of Patients with Moderate Osteoarthritis of Knee. - Nil

Start Date06 Nov 2025

Sponsor / Collaborator

Tiger Companies

NCT06932848

/ Not yet recruitingNot ApplicableIIT

The Therapeutic Effect of Curcumin in Nanogels Compared to 0.1% Fluocinolone Acetonide Oral Paste in the Management of Atrophic-Erosive Oral Lichen Planus

This randomized, double-blind clinical trial evaluates the therapeutic effects of curcumin in nanogels compared to 0.1% fluocinolone acetonide oral paste in the management of atrophic-erosive oral lichen planus (OLP). The study aims to determine whether curcumin nanogels, a natural treatment with enhanced bioavailability, are as effective and better tolerated than standard corticosteroid therapy.

Start Date01 Jun 2025

Sponsor / Collaborator

University of Chulalongkorn

NCT05947513

/ RecruitingNot ApplicableIIT

Feasibility, Safety, and Efficacy of Concomitant Curcumin in Patients Undergoing Palliative Radiotherapy for FIGO Stage IIIB-IVA Cervical Cancer: An Open-label Pilot Trial

The goal of this clinical trial is to test curcumin as an adjunct treatment in patients with cervical cancer receiving standard-of-care palliative radiation. The main questions it aims to answer are:
1. Is adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients feasible? Is conducting this study feasible?
2. Does adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients improve therapeutic responses?
3. Is adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients safe?
4. How much curcumin is absorbed into the body and how long will it stay in the body?
Participants will:
i. Take 250 mg curcumin capsules four times per day for 4-6 weeks in addition to the prescribed palliative radiotherapy.
ii. Provide blood and urine samples for laboratory tests. iii. Provide blood samples to measure curcumin levels in their body. iv. Obtain CT-scan to measure their tumor response. v. Complete questioners to measure improvements to their quality of life, if any.

Start Date10 Apr 2025

Sponsor / Collaborator

Addis Ababa University

100 Clinical Results associated with Curcumin

100 Translational Medicine associated with Curcumin

100 Patents (Medical) associated with Curcumin

39,405

Literatures (Medical) associated with Curcumin

31 Dec 2025·Epigenetics

An overview of potential of natural compounds to regulate epigenetic modifications in colorectal cancer: a recent update

Review

Author: Duttaroy, Asim K. ; Philip, Neha ; Pathak, Surajit ; Siripragada, Sravani ; Banerjee, Antara ; Roy, Susmita ; Deka, Dikshita ; Ayyadurai, Pavithra ; Kondaveeti, Suresh Babu

Colorectal cancer (CRC) remains an alarming global health concern despite advancements in treatment modalities over recent decades. Among the various factors contributing to CRC, this review emphasizes the critical role of epigenetic mechanisms in its pathogenesis and progression. This review also describes the potential role of natural compounds in altering the epigenetic landscape, focused mainly on DNA methylation, histone modification, and non-coding RNAs. Publications from the previous five years were searched and retrieved using well-known search engines and databases like PubMed, Google Scholar, and ScienceDirect. Keywords like CRC/colorectal cancer, CAC/Colitis associated CRC, inflammasomes, epigenetic modulation, genistein, curcumin, quercetin, resveratrol, anthocyanins, sulforaphane, and epigallocatechin-3-gallate were used in various combinations during the search. These natural compounds predominantly affect pathways such as Wnt/β-catenin, NF-κB, and PI3K/AKT to suppress CRC cell proliferation and oxidative stress and enhance anti-inflammation and apoptosis. However, their clinical use is restricted due to their low bioavailability. However, multiple methods exist to overcome challenges like this, including but not limited to structural modifications, nanoparticle encapsulations, bio-enhancers, and novel advanced delivery systems. These methods improve their potential as supportive therapies that target CRC progression epigenetically with fewer side effects. Current research focuses on enhancing epigenetic targeting to control CRC progression while minimizing side effects, emphasizing improved specificity, bioavailability, and efficacy as standalone or synergistic therapies.

31 Dec 2025·ANNALS OF MEDICINE

Effect of curcumin on methotrexate-induced ovarian damage and follicle reserve in rats: the role of PARP-1 and P53

Article

Author: Karaoluk, Nesibe ; Keçeci, Mete

BACKGROUND:

Methotrexate (MTX) is an agent used in the treatment of many neoplastic and non-neoplastic diseases and is known to cause oxidative damage in normal tissues. Curcumin (Cur) is a natural polyphenol compound with powerful antioxidant and antiapoptotic effects. In this study we investigate the effects of Cur on MTX-induced ovarian damage.

MATERIALS AND METHODS:

Thirty-two young adult female Wistar albino rats were divided into four groups: (1) Control (n = 8): only vehicle group, (2) Cur (n = 8): Cur-only group (200 mg/kg/day), (3) MTX (n = 8): MTX-only group (0.35 mg/kg/day), (4) MTX+Cur (n = 8): The group was given MTX (0.35 mg/kg/day) and Cur (200 mg/kg/day) for 28 days. Then, SOD, CAT, MDA, AMH levels were measured using ELISA kits. Follicle count was performed on H&E stained slides. In addition, the expressions of P53 and PARP-1 were analysed by immunohistochemistry.

RESULTS:

MDA levels were seen to be higher in the MTX group than in the MTX+Cur group (p < 0.05). Cur treatment lowered MDA levels and increased SOD and CAT levels (p < 0.05 for all). In the MTX+Cur group, atretic follicle count decreased (p < 0,05), however, primordial follicle count increased (p < 0,01). Secondary follicle count and AMH levels were higher in MTX-treated groups (p < 0,05 and p < 0,01, respectively). Expressions of p53 and Poly [ADP-ribose] polymerase 1 (PARP-1) increased significantly in the MTX group compared to the other groups (p < 0,05).

CONCLUSION:

Cur pretreatment prior to MTX administration may be an effective option in preserving the ovarian follicle pool by regulating P53 and PARP-1 expressions with its antioxidant effect.

31 Dec 2025·Future Science OA

Polymeric nanoparticles-based targeted delivery of drugs and bioactive compounds for arthritis management

Review

Author: Vaidya, Anuradha ; Ravindran, Selvan ; Dixit, Tanu

This review explores the potential of polymeric nanoparticles (PNPs) as targeted drug delivery systems for arthritic treatment, overcoming the limitations of the present therapy. A thorough literature search was conducted on the databases PubMed, Scopus, and Web of Science to find published articles on the use of polymeric nanoparticles in the treatment of arthritis. This includes synthesis methods, mechanisms in drug delivery, and applications of PNPs. Polymeric nanoparticles showed excellent promise in the management of arthritis through enhanced stability of drugs, controlled and sustained drug release, and reduced systemic side effects. Some of the highlighted biocompatible and targeting capabilities of natural and synthetic polymers include chitosan, hyaluronic acid, and PLGA. Bioactive compounds such as curcumin and resveratrol delivered by PNPs enhanced therapeutic efficacy in preclinical arthritis models. Despite their promise, challenges such as rapid clearance and manufacturing scalability remain critical barriers. Polymeric nanoparticles offer a transformative approach to arthritis management by enabling targeted, sustained, and safe drug delivery. Translation into clinical applications would thus require developments in nanoparticle design, personalized medicine, and scalable production techniques.

News (Medical) associated with Curcumin

12 Jun 2025

·www.prnewswire.com

Vascarta Receives FDA Orphan Drug Designation for Vasceptor® in the Treatment of Sickle Cell Disease

SUMMIT, N.J., June 12, 2025 /PRNewswire/ -- Vascarta Inc., a biopharmaceutical company committed to advancing innovative therapies for underserved patient populations, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead drug candidate, Vasceptor® (VAS-101), for the treatment of Sickle Cell Disease (SCD). Orphan Drug Designation is awarded to therapies intended to treat rare diseases that affect fewer than 200,000 people in the United States. This designation provides significant benefits, including seven years of market exclusivity upon approval, tax credits for qualified clinical trials, and exemption from certain FDA fees. "The attainment of Orphan Drug Designation represents an important regulatory milestone for Vascarta and underscores the therapeutic potential of Vasceptor® to provide safe and effective relief to patients living with this debilitating disease," said Dr. Richard Prince, CEO & President of Vascarta. "We plan to work closely with the United States Food & Drug Administration to bring Vasceptor® to market as rapidly as possible." Dr. Joel Friedman, Professor, Department of Microbiology & Immunology, Albert Einstein College of Medicine, and Vascarta Scientific Founder & Head, Scientific Advisory Board, stated, "The preclinical results to date showing pain reduction and therapeutic efficacy resulting from our novel approach of targeting red blood cell instability, neuro-inflammation and vascular inflammation bodes well for the development of a widely accessible therapy that prevents and treats many if not most of the clinical consequences of SCD." Vasceptor® is exclusively licensed to Vascarta from the Albert Einstein College of Medicine (Bronx, New York, USA). About Vasceptor® ( VAS-101) VAS-101, developed by Vascarta Inc. (Summit, NJ, USA), is a patented topical curcumin formulation that is delivered using patented transdermal technology and that is designed to overcome the limited bioavailability and suboptimal effectiveness of oral dosing of curcumin. A study in PNAS Nexus suggests VAS-101 may reduce chronic pain, stabilize red blood cells, and lower inflammation in sickle cell disease (SCD). It is currently in a Phase 1 clinical trial at the Foundation for Sickle Cell Disease Research (FSCDR) in Hollywood, Florida. While curcumin is known for its safety and anti-inflammatory, antioxidant, and anti-sickling properties, its clinical use has been limited by poor oral bioavailability. About Sickle Cell Disease Sickle Cell Disease is the most common inherited genetic disorder that affects primarily African American and non – Hispanic Black individuals in the United States. SCD associated complications include anemia, acute and chronic pain, infections, pneumonia and acute chest syndrome, stroke, kidney, liver, and heart disease. Current estimates indicate there are 175,000 cases of SCD in the USA and 45,000 in European Union countries. The estimated life expectancy of those with sickle cell disease in the USA is more than 20 years shorter than the average expected lifespan. SCD is caused by a single point mutation in the globin gene leading to sickling of red blood cells. It is characterized by severe pain, inflammation, oxidative stress, and organ damage, which contributes to the poor quality of life and reduced survival. Recently approved SCD therapies do not mitigate pain, and patients are often on multiple drugs which often have undesirable side effects. The unmet medical need for most SCD sufferers is significant. Better therapies that are safe, improve outcomes, optimize compliance for patients of all ages, minimize the need for blood transfusions, and reduce the need for chronic administration of potentially harmful pain medications are needed. About Vascarta Vascarta Inc. is a clinical stage pharmaceutical company developing efficient transdermal and transmucosal delivery of pharmaceuticals to address inflammatory conditions with an initial focus on Sickle Cell Disease and osteoarthritis. To learn more, contact Vascarta Chairman, CEO & President, Dr. Richard Prince, at [email protected]. Media requests should be directed to David Hymson at [email protected]. SOURCE Vascarta Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1Orphan DrugDrug Approval

10 Dec 2024

·www.prnewswire.com

Highly bioavailable transdermal gel from Vascarta may offer a safe and effective new way to treat sickle cell disease - presentation at American Society of Hematology Conference

SAN DIEGO, Dec. 10, 2024 /PRNewswire/ -- Vascarta Inc. ("Vascarta") reported new research findings at the 66th Annual American Society of Hematology meeting in San Diego showing that their novel transdermal preparation of curcumin reduces nerve and organ damage while improving red blood cell health in humanized sickle cell mice. Continue Reading Vasceptor® is currently available from a 503a compounding pharmacy licensed in 22 states. Based on these and previous results in pre-clinical studies showing reduced pain, Vascarta's transdermal curcumin gel will be clinically tested next year in human sickle cell disease (SCD) sufferers by the Foundation for Sickle Cell Disease and Research (FSCDR (Hollywood, Florida, USA). In SCD, red blood cells (RBCs) are unstable. The unstable RBCs tend to release free hemoglobin and heme which sets in motion pro-inflammatory and oxidative processes that promote nerve and organ damage. There is a critical need for an FDA-approved treatment that is safe, prevents and treats SCD sequelae, and is easy to self-administer. As described in the American Society of Hematology meeting poster*, when humanized sickle cell mice were exposed to inflammation and oxidative stress associated with SCD, they experienced nerve, organ, and RBC damage, leading to pain. However, when scientists at the University of California – Irvine applied Vascarta's transdermal curcumin gel to humanized sickle cell mice, and to nerve tissue removed from these mice, they demonstrated reduced nervous tissue damage. Improvements were seen in the hippocampal neurons of the brain in the central nervous system and in dorsal root ganglia neurons in the peripheral nervous system. There was also clear evidence of reduced inflammation-induced activation of microglia in the brain - which is an essential step in protecting the central nervous system from the consequences of SCD - and reduced oxidative damage to the spinal cord. Experiments conducted by the FDA's Center for Biologics Evaluation and Research (CBER) showed the transdermal curcumin treatment of SCD mice i) improved the mitochondrial bioenergetic parameters in the heart, ii) reduced oxidative stress and iii) increased bioenergetic capacity in RBCs, all of which contribute to the complex constellation of symptoms observed in SCD patients. Principal investigator, Professor Kalpna Gupta (University of California – Irvine), stated that: "These breakthrough findings about the beneficial effects of the transdermal curcumin gel on nervous system, organs, and red blood cells were generated through collaboration among scientists from several institutions, including the University of California – Irvine, the US Food and Drug Administration (FDA), and Albert Einstein College of Medicine." Professor Joel Friedman (Albert Einstein College of Medicine and inventor of Vascarta's patented transdermal drug delivery technology) explained that: "The positive sickle cell results are consistent with multiple other preclinical studies that have shown, for example, therapeutic benefits of transdermal curcumin for inflammation, pain, cytokine storm, endothelial integrity, hypertension, aging." Dr. Richard Prince, Vascarta Chairman and CEO, commented that: "We are excited that these findings, along with other favorable pre-clinical results showing reduced pain, give us the confidence to progress into human clinical testing among sickle cell patients." *" Mechanism-based treatable targets for organ damage and pain in sickle cell disease" About Sickle Cell Disease Sickle cell disease is the most common inherited disease that primarily affects African Americans and Hispanics in the United States. Individuals with sickle cell disease may experience serious health complications, such as chronic pain, stroke, lung problems, eye problems, infections, and kidney disease, along with periodic acute pain crises. About Vascarta Inc. Vascarta is a clinical-stage pharmaceutical company developing transdermal delivery of pharmaceuticals to address several conditions including sickle cell disease, arthritis, hypertension, cancer, and aging. More information regarding Vascarta's existing research or future collaborations can be found at . Publication Authors & Affiliations Yugal Goel1, Sirsendu Jana2, Mya A. Arellano1, Reina A. Lomeli1, Graham J. Velasco3, Donovan A. Argueta1, Richard Prince4, Abdu I. Alayash2, Joel Friedman4,5, Kalpna Gupta1,6* 1Hematology/Oncology Division, Department of Medicine, University of California, Irvine, CA, USA; 2Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA; 3Pathology Department, VA Long Beach Healthcare System, Long Beach, CA; 4Vascarta Inc, Summit, NJ; 5Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA; 6Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA. Corresponding Publication Author Email: [email protected] Vascarta contact: Richard Prince, PhD – Chairman & Chief Executive Officer Email: [email protected] SOURCE Vascarta Inc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ASHClinical Result

28 Oct 2024

·www.prnewswire.com

Cocrystal Health Industry Announces Launch of Best in Class Bioabsorption and Stability Cocrystallized Lutein and Curcumin Technologies

Patented and clinically verified nutraceutical actives outperform current branded offerings and offer a powerful solution for supplement product potency concerns. LAS VEGAS, Oct. 28, 2024 /PRNewswire/ -- At the Supplyside West tradeshow this week representatives from Cocrystal Health Industry are announcing the launch of the Cocrystal Lutein and Curcumin powder actives. Backed by 60 global patents and near 100 published papers, the company leverages their proprietary and clean cocrystallization platform to produce actives with dramatically improved bioabsorption, stability and functionality relative to existing offerings. These launches build on their existing cocrystallized ingredient portfolio which includes Ubiquinol CoQ10, Hydroxytyrosol and Alpha Tocopherol Vitamin E. Continue Reading Cocrystal Curcumin Powder Cocrystal Lutein Powder Lutein is well demonstrated in clinical research to support eye health, though traditional lutein ingredients have poor bioabsorption, solubility, and stability, as the ingredient is easily oxidized. Powered by Cocrystal Health Industry's clean, vegan and non-GMO cocrystallization process, Cocrystal Lutein now provides a powerful solution to address these concerns. In 3rd party testing, Cocrystal Lutein demonstrated over 6 times greater bioabsorption and 3 times better solubility compared to current marketed lutein. In a head-to-head capsule stability study, the cocrystal advantage is even more dramatic. Cocrystal Lutein maintained over 99% of potency in capsules after 30 days, while current marketed lutein maintained less than 2% of its original potency. In addition to performance advantages, the cocrystal technology offers a significant cost savings relative to well known branded lutein. While well researched to support a range of benefits including joint and cognitive health, marketed curcumin extracts are similarly limited by very poor bioavailability. Patented Cocrystal Curcumin featuring L-Carnitine as a ligand has been shown in studies to offer over 10X greater bioabsorption in comparison to current marketed curcumin. And while there are several enhanced bioavailability curcumin materials available, in a head-to-head study Cocrystal Curcumin showed significantly better bioabsorption even relative to an existing enhanced offer. Alex Mei, PhD, Cocrystal Health Industry's Founder & CEO commented, "We are thrilled to expand our portfolio and introduce powerful new solutions in our Cocrystal Lutein & Curcumin technologies. Our proprietary platform solves for multiple nutrition brand concerns – providing meaningful differentiation and unparalleled benefit performance to their consumers, while ensuring sustained potency against label claim. As the global leader in cocrystallized active ingredients, we're proud to offer these transformative solutions." To learn more manufacturers and formulators can reach out to [email protected]. About Cocrystal Health Industry: Backed by 60 global patents and near 100 published papers, Cocrystal Health Industry introduces cocrystal powder technologies as unprecedented solutions for poor stability and low bioavailability ingredients. With demonstrated best in class bioavailability and superior in-formula stability, our actives also feature pure nature integrity, improved solubility, dissolution, melting point and flowability versus existing offerings. Beyond their superior performance, Cocrystal actives typically offer a cost advantage relative to other branded ingredients. The company's growing portfolio includes Cocrystal Ubiquinol, Hydroxytyrosol, Alpha Tocopherol, Rutin and now Lutein and Curcumin. For more information visit . Media Contact: Jeff Avila 305-632-1733 [email protected] SOURCE Cocrystal Health Industry WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Curcumin

External Link

KEGG	Wiki	ATC	Drug Bank
-	Curcumin	-	DB11672

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Inflammation	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Localized Prostate Carcinoma	Phase 3	United States	The University of Texas Southwestern Medical Center	11 Mar 2019
Crohn Disease	Phase 3	France	3i Nature SAS	01 Dec 2014
Adenocarcinoma of prostate	Phase 3	United States	The University of Texas Southwestern Medical Center	01 May 2014
Colorectal Cancer	Phase 3	-	University of Pennsylvania	-
Colorectal Cancer	Phase 3	-	The University of Texas MD Anderson Cancer Center	-
Conjunctivitis, Allergic	Phase 3	-	University of Pennsylvania	-
Conjunctivitis, Allergic	Phase 3	-	The University of Texas MD Anderson Cancer Center	-
Optic Atrophy, Hereditary, Leber	Phase 3	-	The University of Texas MD Anderson Cancer Center	-
Optic Atrophy, Hereditary, Leber	Phase 3	-	University of Pennsylvania	-
Stomatitis	Phase 3	-	University of Pennsylvania	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02944578 (CTgov)	Phase 2	Uterine Cervical Dysplasia \| Cervical Intraepithelial Neoplasia	7	Curcumin (Curcumin)	tshkbdnuhh = ocgzbnsnkk wnkcewyoxq (wpsfftrnix, vmnfvsuhzi - pxkhmaywkq) View more	-	29 Oct 2024
				placebo (Placebo)	tshkbdnuhh = xherpgjagk wnkcewyoxq (wpsfftrnix, bumllvcocy - ydqrazcpvn) View more
NCT03223883 (CTgov)	Phase 2	Cognitive Dysfunction \| Chronic Kidney Diseases	94	Curcumin (Curcumin)	smjptvxjad(upuddlntwt) = zhlmspdmja gcxqwzuajf (wrzokrfdit, rqeaveydor - wrqgdakmfh) View more	-	08 Oct 2024
				Placebo (Placebo)	smjptvxjad(upuddlntwt) = wzsoerljtk gcxqwzuajf (wrzokrfdit, lyyybhulan - sexaioizkr) View more
NCT04205929 (CTgov)	Phase 4	Hemorrhage \| Metrorrhagia	58	Placebo (Placebo Group)	tnhshzvilk(kwcyrcieae) = pbcshftnbd vptlyomwgf (cyoboahaod, 4.8) View more	-	03 Jul 2024
				Curcumin (Curcumin Group)	tnhshzvilk(kwcyrcieae) = xytrukxhws vptlyomwgf (cyoboahaod, 6.9) View more
ENDO2024	Not Applicable	Pituitary Apoplexy	-	Curcumin	vouszagcyg(asepuslqus) = jvfawuzekj udvxtntaww (ikoyivsfik ) View more	-	01 Jun 2024
				IV dexamethasone	vouszagcyg(asepuslqus) = zggoamassp udvxtntaww (ikoyivsfik ) View more
NCT02100423 (CTgov)	Phase 2	Chronic Lymphocytic Leukemia \| B-Cell Lymphoma \| Small Lymphocytic Lymphoma	35	pharmacological study+cholecalciferol+Curcumin	cwcscbopzn = tspiqmetvn kszsaeczja (njnpuyyujp, ggfelgvtnq - fgkdnpwpfq) View more	-	12 Apr 2024
NCT02782949 (CTgov)	Phase 2	Carcinogenesis \| Gastritis, Atrophic \| Stomach Cancer	50	Quality-of-Life Assessment+Curcumin (Arm I (Curcumin))	doinuytaxl(asppbypwwe) = qwbpbmmeop cizeibddjd (eibghlumdo, mmuavxmiru - behvpjnpba) View more	-	05 Mar 2024
				Quality-of-Life Assessment (Arm II (Placebo))	doinuytaxl(asppbypwwe) = rrhocbcbfu cizeibddjd (eibghlumdo, xbitmpqwop - wxeceaxbcu) View more
EASL_LCS2023	Not Applicable	Hepatocellular Carcinoma	-	Curcumin	jwvaertxbi(jdvknrcbbe) = 30 µM curcumin treatment in Huh-7 cells was able to significantly repress the expression of both HOTAIR jhwayummrb (ixvkcwwkfp ) View more	-	20 Apr 2023
PD16-01 (AUA2023)	Not Applicable	Prostatic Cancer	-	Lactoferrin	siuedohceo(djysohihul) = lrqrylvuad uxgnrjdluf (ngycwnbqqp )	-	01 Apr 2023
				Curcumin + Lactoferrin	siuedohceo(djysohihul) = llabsjowsa uxgnrjdluf (ngycwnbqqp )
EP-55 (EANM2022)	Not Applicable	-	-	Curcumin gold nanoparticles (C-AuNPs)	isymitmsus(cjvufqhulh) = 0.35 tyugdxdwts (freyfcnigb ) View more	-	22 Sep 2022
SNMMI2022	Not Applicable	Thyroid Cancer	90	40 mg nano-curcumin	jirmkcuwpl(cnplibixzp) = umrpszzeyv uwteqdhhmb (qndufngmba, 0.58) View more	Positive	08 Aug 2022
				80 mg nano-curcumin	jirmkcuwpl(cnplibixzp) = ckdxhnxfwo uwteqdhhmb (qndufngmba, 0.85) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis